SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A strong third-quarter report and raised revenue outlook, driven by demand for Mounjaro and Zepbound, are fueling Lillys breakout and a wave of analyst upgrades. Traders are also weighing the growth outlook against a lower profit forecast tied to acquisition-related R&D charges, weaker-than-expected Foundayo sales and concerns about valuation.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders weigh Middle East supply risksespecially reported attacks and threats around the Strait of Hormuzagainst possible US-Iran negotiations that could ease oil prices. Bulls cite disrupted flows and escalation risks, while bears argue that a deal or de-escalation could quickly unwind the geopolitical premium.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake is drawing attention as traders await the FDAs decision on whether to accept its sonelokimab application for hidradenitis suppurativa and what review timeline it will receive. The community is split between optimism about the drug and upcoming regulatory milestone and concern over approval risk, commercialization plans, and continued weakness in biotech shares.

The Clorox Co. engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segments consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment refers to food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment covers products sold outside the United States, excluding natural personal care products. The company was founded by Edward Hughes, Charles Husband, William Hussey, Rufus Myers, and Archibald Taft on May 3, 1913 and is headquartered in Oakland, CA.

Clorox Co.

Cloroxs steep decline has fueled debate over its turnaround, with investors split between buying the beaten-down dividend stock and worrying about weak sales, execution and dividend sustainability. Upcoming quarterly results and the incoming CEOs ability to revive growth are also in focus.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS is drawing attention ahead of its quarterly report, with traders weighing whether guidance can hold against concerns about its Caremark PBM business and Aetnas Medicare Advantage outlook. Some see an undervalued, defensive healthcare business, while others remain wary of the operating and reimbursement pressures.

Wells Fargo & Co. is a diversified and community-based financial services company, which engages in the provision of banking, insurance, investments, mortgage, and consumer and commercial finance products and services. It operates through the following segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth and Investment Management. The Consumer Banking and Lending segment offers consumer and small business banking, home lending, credit cards, auto, and personal lending. The Commercial Banking segment provides banking and credit products across industry sectors and municipalities, secured lending and lease products, and treasury management. The Corporate and Investment Banking segment is composed of corporate banking, investment banking, treasury management, commercial real estate lending and servicing, and equity and fixed income solutions, as well as sales, trading, and research capabilities. The Wealth and Investment Management segment refers to personalized wealth management, brokerage, financial planning, lending, private banking, trust, and fiduciary products and services. The company was founded by Henry Wells and William G. Fargo on March 18, 1852 and is headquartered in San Francisco, CA.

Wells Fargo & Co.

Wells Fargos Q3 results are driving attention: earnings topped expectations, but a revenue and net interest income shortfall, alongside higher loan-loss provisions, weighed on shares. Traders are split between concern over lending trends and the view that profit growth and healthy business activity remain supportive.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Schwab and thinkorswim platform outages are drawing attention, with many users reporting login problems, inaccurate quotes, and inability to place or manage trades. Frustration is widespread, and some traders say the recurring reliability issues are prompting them to consider moving to other brokerages.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is falling with semiconductor and technology stocks as Intels weak outlook and broader doubts about AI infrastructure spending and returns pressure the sector ahead of AMDs earnings. Traders debate whether the move is sympathy sellingwith some arguing Intels struggles could benefit AMDor a warning about stretched valuations and cooling AI expectations.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs October deliveries rose month over month, prompting debate over whether the growth can support its ambitious fourth-quarter delivery pace. Bulls see the delivery trend as evidence of demand, while skeptics remain focused on uncertainty around guidance and the stocks prolonged decline.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Discussion is dominated by GameStop warrants reportedly expiring worthless, with traders split over whether that removes a dilution overhang or leaves warrant holders with losses and reflects poorly on management. Speculation about Roaring Kittys changed X profile and a possible return is adding excitement, but no return is confirmed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance 

Insmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.

Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday

Stocks rallied on strong earnings and raised guidance, led by Huntington Ingalls, Porch, Teladoc and Crocs, despite the Dow falling 150 points.read more...

Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of -35.29% and +4.62%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update

Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update Insmed Reports Third-Quarter 2026 Financial Results and Provides Business UpdatePR NewswireBRIDGEWATER, N.J., Oct. 29, 2026 Total Company Revenues of $524.4 Million for the Third Quarter of 2026BRINSUPRI(brensocatib...

Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know

Kura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

$100 Invested In Insmed 15 Years Ago Would Be Worth This Much Today

Insmed (NASDAQ:INSM) has outperformed the market over the past 15 years by 11.42% on an annualized basis producing an average annual return of 24.03%. Currently, Insmed has a market capitalization of $20.89 billion.read more...

Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Top 3 Health Care Stocks That Could Blast Off In October

Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.read more...

Insmed Appoints Two New Directors to Its Board

Insmed Appoints Two New Directors to Its Board Insmed Appoints Two New Directors to Its BoardPR NewswireBRIDGEWATER, N.J., Oct. 20, 2026 Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New...

$INSM Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.46 up 73.71% YoY
• Reported revenue of $524.43M up 268.43% YoY
• Insmed raised full-year 2026 revenue guidance for BRINSUPRI to $1.35B to $1.4B and ARIKAYCE to $460M to $470M, from prior guidance.

Stocktwits

Insmed Inc

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.46 up 73.71% YoY
• Reported revenue of $524.43M up 268.43% YoY
• Insmed raised full-year 2026 revenue guidance for BRINSUPRI to $1.35B to $1.4B and ARIKAYCE to $460M to $470M, from prior guidance.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of -$0.46 up 73.71% YoY
• Reported revenue of $524.43M up 268.43% YoY
• Insmed raised full-year 2026 revenue guidance for BRINSUPRI to $1.35B to $1.4B and ARIKAYCE to $460M to $470M, from prior guidance.

Insmeds R&D and SG&A expenses exceeded their year-ago levels, the company reported a third-quarter net loss, and ARIKAYCEs U.S. indication is limited while clinical benefit has not yet been established.

Insmeds BRINSUPRI and ARIKAYCE revenues grew, BRINSUPRI launched in Japan as the first and only MHLW-approved NCFB treatment, and TPIP Phase 3 programs advanced across four indications.

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study 

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Insmed said that it will subsequently discontinue development of brensocatib in hidradenitis suppurativa</li><li>Martina Flammer, Chief Medical Officer of Insmed, said that the company was disappointed with the results.</li><li>According to data from Koyfin, &nbsp;all of the 20 analysts covering INSM stock rate it ‘Buy’ or higher.</li></ul>Insmed Incorporated (INSM) said on Tuesday that its mid-stage study evaluating brensocatib in adult patients with moderate to severe hidradenitis suppurativa failed to meet its goals.Shares of the company fell 2% after hours.<h2 class="st-heading-2">Study Results</h2>The mid-stage trial was aimed at evaluating the safety and efficacy of brensocatib in adults with moderate to severe hidradenitis suppurativa, a chronic, non-contagious inflammatory skin condition characterized by painful, recurring lumps and abscesses. &nbsp;The trial did not meet the primary or secondary endpoints in either the 10 mg or 40 mg treatment arms though the drug was well tolerated, the company said. The study enrolled 214 patients and its primary goal was a reduction in total abscess and inflammatory nodule at 16 weeks.Participants of the study experienced a 45.5% and 40.3% reduction from baseline in total abscess and inflammatory nodule (AN) count in the brensocatib 10 mg and 40 mg arms, respectively, compared to a 57.1% reduction in the placebo arm, the company said.Insmed said that it will subsequently discontinue development of brensocatib in hidradenitis suppurativa. Martina Flammer, Chief Medical Officer of Insmed, said that the company is “disappointed” with the results.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around INSM stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.According to data from Koyfin, all 20 analysts covering INSM stock rate it ‘Buy’ or higher. The stock has an average 12-month price target of $214.79, representing a potential upside of about 32% from last closing price.The company currently has two approved therapies, including Brinsupri for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older, and Arikayce for the treatment of certain Mycobacterium avium complex (MAC) lung infections.<a href="https://stocktwits.com/symbol/INSM">INSM stock</a> has more than doubled over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/gopro-shares-edge-up-after-hours-on-23-percent-layoff-announcement/cZJB2feRIqd">GoPro Shares Edge Up After-Hours On 23% Layoff Announcement</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Insmed Incorporated logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The trial did not meet the trials’s primary or secondary endpoints in either the 10 mg or 40 mg treatment arms, though the drug was well tolerated, the company said. 

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$112.58
Prev Close	$111.59
Open	$113.60
Dividend Yield	0.00%
50-Day Moving Average	$112.66
Beta	0.77
Avg. Volume	2.12M
PE Ratio	-39.98

52-Week High	$212.75
52-Week Low	$90.39
Market Capitalization	$24.7B
EPS (Annual)	-$6.42
Price to Book	34.00
Revenue Per Employee	$364,436.90

Feed

News

Sentiment

Earnings

Fundamentals

Info

INSM Fundamentals